Delving into the Latest Updates on PRG-D with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCongenital Disorders+ [3]

Active Indication

Bloom SyndromeCockayne Syndrome

Inactive Indication-

Originator Organization

PRG S&T Co., Ltd

Active Organization

PRG S&T Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

During the process of optimization of pargamicin A (PRG-A) production, we discovered new active components PRG-B (I, R¹=R²=H, R³=Et), PRG-C (I, R¹=OH, R²=H, R³=Et), and PRG-D (I, R¹/R²=carbonyl, R³=Et) in the culture broth of the PRG-A-producing strain Amycolatopsis sp. ML1-hF4.The present study investigates the fermentation, isolation, structural elucidation, and antimicrobial activities of these new PRG-A analogs and discusses the structure-activity relation of PRGs.PRG-A and PRG-C exhibited potent antibacterial activity against Gram-pos. bacteria including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis/faecium; the antibacterial activity of PRG-B and PRG-D against these bacteria was weaker.PRG-C and PRG-D, which possess a polar group in the northern region of Pip, exhibited 4-8-fold weaker antibacterial activity against staphylococci than against enterococci, whereas PRG-A and PRG-B showed equal activity against staphylococci and enterococci.

100 Deals associated with PRG-D

Login to view more data